Jaye Viner - Gaithersburg MD, US Yong Chang - Gaithersburg MD, US Jennifer McDevitt - Gaithersburg MD, US
Assignee:
MEDIMMUNE, LLC - Gaithersburg MD
International Classification:
A61K 39/395
US Classification:
4241451, 4241581
Abstract:
Without limitation, this disclosure relates to methods of treating cell proliferation disorders, neoplastic disorders, cancers, tumors and the like using anti-IGF antibodies, or antigen binding fragments thereof. Disclosed herein are methods of treating cancer in a patient, for example a human patient, comprising administering to the patient at least two doses of an antibody which binds both IGF-I and/or IGF-II. The doses are separated by about a week, or by about three weeks, and each dose comprises an amount of antibody greater than about 0.5 mg kg of patient body mass and less than about 50 mg per kg of patient body mass.
- GAITHERSBURG MD, US Yong Chang - Gaithersburg MD, US Jennifer McDevitt - Gaithersburg MD, US
International Classification:
C07K 16/22
Abstract:
Without limitation, this disclosure relates to methods of treating cell proliferation disorders, neoplastic disorders, cancers, tumors and the like using anti-IGF antibodies, or antigen binding fragments thereof. Disclosed herein are methods of treating cancer in a patient, for example a human patient, comprising administering to the patient at least two doses of an antibody which binds both IGF-I and/or IGF-II. The doses are separated by about a week, or by about three weeks, and each dose comprises an amount of antibody greater than about 0.5 mg kg of patient body mass and less than about 50 mg per kg of patient body mass.
Dr. Chang graduated from the University of North Carolina School of Medicine at Chapel Hill in 1991. He works in Carrollton, TX and specializes in Internal Medicine.